Geninus지니너스

Geninus remains deeply loss-making and its shares have fallen sharply over the past year, though it holds ₩13.6B in cash and no borrowings.

Geninus, a Korean genome analysis company spun off from Samsung Medical Center, sells pharmaceutical analysis platforms, research tools and diagnostic tests. Trailing twelve-month revenue to H1 2026 was ₩11.3B against an operating loss of ₩11.9B, and the share price closed at ₩1,443 on 22 October 2026, near its 52-week low of ₩1,439 and well below its high of ₩6,480. The data does not include forecasts or analyst views.

What stands out

• Revenue rose 62.4% in 2025 to ₩10.5B, but the operating loss still widened to ₩11.7B, an operating margin of -111.3%.
• Trailing net loss is ₩20.4B and free cash flow is about -₩5.6B, so the business is burning cash.
• Cash of ₩13.6B and zero borrowings are the main balance-sheet support; liabilities are 34.1% of equity.
• Market capitalisation is about ₩56.8B and the shares are down 25.8% over one month, 31.9% over three months and 24.6% over one year.
• Recent filings are mostly insider shareholding reports and conversion-right exercises, which point to dilution activity; no news headlines were in the data.

What to watch

• The full-year 2026 results and the detail behind the H1 2026 half-year report filed on 14 August 2026.
• Further conversion-right exercises and share issuance, which could add shares outstanding.
• Whether the net loss narrows, since the data shows no profit in any year from 2021 to 2025 and no dividend.